Physician profile
Theodore M Lee
NPI 1689606881
$10,925.39
in general payments reported to CMS, 2019-2025
37 companies · $2,233 in 2025
The $2,233 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $946 · 2020: $599 · 2021: $1,719 · 2022: $1,716 · 2023: $1,744 · 2024: $1,969 · 2025: $2,233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,815 · Education: $72.75 · Consulting Fee: $57.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,815.44 |
| Education | $72.75 |
| Consulting Fee | $57.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,311.77 | 2019-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $1,283.54 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,203.04 | 2020-2025 | Cuvitru, Takhzyro, Hyqvia |
| Genzyme Corporation | $934.96 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $672.39 | 2019-2025 | |
| Covis Pharma Gmbh | $644.71 | 2019-2023 | |
| Grifols USA, LLC | $608.65 | 2019-2025 | Xembify |
| Csl Behring | $532.36 | 2019-2025 | Hizentra, Haegarda |
| Amgen INC. | $482.57 | 2021-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $475.79 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $464.54 | 2019-2025 | Ruconest |
| Pfizer INC. | $267.57 | 2019-2025 | |
| Tersera Therapeutics LLC | $255.77 | 2023-2025 | Quzyttir |
| Blueprint Medicines Corporation | $247.77 | 2021-2025 | Ayvakit |
| Octapharma USA, INC. | $204.37 | 2020-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.